We are a biotechnology company headquartered in Greater Cleveland, Ohio. We develop industrial grade human cells from stem cells at a much faster rate, at dramatically lower cost, and with less R&D risk than is currently the norm in the industry.

Our proprietary HD-DoE™ platform merges developmental biology with cutting-edge robotics, mathematics, and computerized experimental design and analysis to perform process-specific parameter optimization to rapidly develop recipes for the development of any type of human cells for use in the drug discovery process or for therapeutic purposes. These recipes minimize the use of proteins in favor of far more stable and dramatically less expensive small molecules. Reactor-produced human cells have multiple uses, including drug discovery, 3D-organ printing, human disease modeling, and cell-based therapy.

Our current cell programs are focused on developing different types of human cells at large volume for research use in order to accelerate the drug discovery process of pharma and biotech customers and to develop human cells for therapeutic purposes.

Our research use cell program focuses on making neuronal cells for drug discovery programs involving Parkinson’s disease, autism, multiple sclerosis, thrombocytopenia, and obesity, and functional human pancreatic islet cells (beta cells) for drug discovery programs targeting diabetes. We are currently developing midbrain dopaminergic (mDA) neurons, forebrain parvalbumin-expressing interneurons, and oligodendrocytes of the human central nervous system (CNS). In addition, we are developing functionally mature pancreatic beta cells. These cells are critical for accelerating the drug discovery process at pharma and biotech companies working on CNS and diabetes (Type I or II) related therapeutics. We are also developing NPY-expressing neurons and GLP1-expressing neurons for accelerating the drug discovery of obesity treatments.

Medium Spiny Neurons